Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look

Erlend Faltinsen, Morris Zwi, Xavier Castells, Christian Gluud, Erik Simonsen, Ole Jakob Storebø

BMJ evidence-based medicine · 2018 · 38 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

The National Institute for Health and Care Excellence (NICE) recently updated its guideline on pharmacological treatments for attention deficit hyperactivity disorder (ADHD).The guideline builds on evidence reviews with serious methodological limitations concerning multiplicity, imprecision, selective reporting, and short-term data.Strong clinical practice recommendations for methylphenidate and lisdexamfetamine are informed by GRADE-evaluated, low-quality studies and subjective value judgements.This article critically discusses the updated NICE guideline on pharmacological treatments for ADHD and proposes concrete solutions to address the issues at hand.

References

15